What is HC Wainwright’s Estimate for Sernova Q3 Earnings?

Sernova Corp. (TSE:SVA) – Stock analysts at HC Wainwright issued their Q3 2026 earnings estimates for Sernova in a research report issued on Tuesday, September 8th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share. HC Wainwright also issued estimates for Sernova’s Q4 2026 earnings at ($0.01) EPS.

Sernova Trading Up 7.7%

TSE SVA opened at C$0.14 on Thursday. The company has a current ratio of 0.14, a quick ratio of 18.11 and a debt-to-equity ratio of -25.45. Sernova has a 1-year low of C$0.10 and a 1-year high of C$0.20. The firm’s fifty day simple moving average is C$0.11 and its 200-day simple moving average is C$0.14. The company has a market capitalization of C$52.87 million, a PE ratio of -3.50 and a beta of -0.43.

Sernova (TSE:SVA) last released its earnings results on Thursday, June 11th. The company reported C$0.01 earnings per share (EPS) for the quarter.

About Sernova

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.